Avalo Therapeutics up on enrollment completion for asthma treatment trial
17/01/2023 18:06
** Shares of drug developer Avalo Therapeutics Inc AVTX.O
gain 3.4% to $5.03
** Co says it has completed target enrollment in its
mid-stage study for experimental therapy, AVTX-002, for treating
a type of asthma
** Co plans to report topline data from trial in Q2 2023
** AVTX-002 is a monoclonal antibody and is co's lead
development asset
** Avalo shares are up ~8% in the past 6 months
(Reporting by Raghav Mahobe)
((Raghav.Mahobe@thomsonreuters.com;))